Sajad Sahab-Negah - Neuroscience Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran
Elham Poonaki - Neuroscience Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran
Fatemeh Ariakia - Neuroscience Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran
Mohammad Jalili-Nik - Neuroscience Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran

Glioblastoma multiform (GBM) is the most malignant form of brain tumors in adults. Recent achievements have shown that cancer therapy failure, GBM recurrence and short life survival in these patients are associated with existence of self-renewing CD133 positive cancer stem cells (CSCs) in GBM. In this study, PTC-209 (BMI-1 inhibitor) utilized to load into PLGA-PEG nanoparticle conjugated with CD133 as a targeted delivery to suppress growth of CSCs in the GBM. Primary GBM cells derived from two patients who suffered from GBM and U87 as a GBM cell line have been cultured in this study. Cells were treated based on IC50 treated by polymeric nanoparticle of BMI-inhibitorin different doses. Proliferation, viability, and migration were assessed by MTT, live/dead, and wound healing assay, respectively. our results showed that polymeric nanoparticle formulation of BMI-inhibitor significantly decreased proliferation, viability, and migration of CSCs. BMI-1 inhibitor delivered by PLGA may have great potential for eradicating CSCs in the future if further experiments could confirm these achievements.